Exacerbated synucleinopathy in mice expressing A53T SNCA on a Snca null background

被引:67
作者
Cabin, DE
Gispert-Sanchez, S
Murphy, D
Auburger, G
Myers, RR
Nussbaum, RL
机构
[1] NHGRI, NIH, Bethesda, MD 20892 USA
[2] Univ Hosp, Inst Expt Neurobiol, Frankfurt, Germany
[3] NINDS, NIH, Bethesda, MD 20892 USA
[4] Univ Calif San Diego, La Jolla, CA 92093 USA
[5] San Diego VA Healthcare Syst, San Diego, CA USA
[6] Univ Hosp, Neurol Clin, Frankfurt, Germany
关键词
Parkinson's disease; alpha-synuclein; mouse models; neurodegeneration; Wallerian degeneration; pale bodies;
D O I
10.1016/j.neurobiolaging.2004.02.026
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
alpha-Synuclein is a major component of Lewy bodies, neuronal inclusions diagnostic for Parkinson's disease (PD). While an Ala53Thr mutation in alpha-synuclein can cause PD in humans, in mice the wildtype residue at position 53 is threonine, indicating that mice are either too short-lived to develop PD, or are protected by the six other amino acid differences between the proteins in these two species. Mice carrying an Ala53Thr human SNCA transgene driven by the mouse prion promoter show a mild movement disorder and only rarely develop severe pathology by 2 years of age. To determine whether the presence of mouse alpha-synuclein affects the pathogenicity of the human protein, the transgene was crossed into mice lacking endogenous alpha-synuclein. Mice that express only human alpha-synuclein developed a neuronopathy characterized by limb weakness and paralysis with onset beginning at 16 months of age. The neuronopathy is probably due to high levels of expression of the transgene in the ventral spinal cord leading to motor neuron damage and Wallerian degeneration of the ventral roots. These data suggest mouse alpha-synuclein is protective against the deleterious effects of the human mutant protein. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:25 / 35
页数:11
相关论文
共 34 条
  • [1] The HD mutation causes progressive lethal neurological disease in mice expressing reduced levels of huntingtin
    Auerbach, W
    Hurlbert, MS
    Hilditch-Maguire, P
    Wadghiri, YZ
    Wheeler, VC
    Cohen, SI
    Joyner, AL
    MacDonald, ME
    Turnbull, DH
    [J]. HUMAN MOLECULAR GENETICS, 2001, 10 (22) : 2515 - 2523
  • [2] Chronic systemic pesticide exposure reproduces features of Parkinson's disease
    Betarbet, R
    Sherer, TB
    MacKenzie, G
    Garcia-Osuna, M
    Panov, AV
    Greenamyre, JT
    [J]. NATURE NEUROSCIENCE, 2000, 3 (12) : 1301 - 1306
  • [3] Cabin DE, 2002, J NEUROSCI, V22, P8797
  • [4] PROGRESSIVE NEURONOPATHY IN TRANSGENIC MICE EXPRESSING THE HUMAN NEUROFILAMENT HEAVY GENE - A MOUSE MODEL OF AMYOTROPHIC-LATERAL-SCLEROSIS
    COTE, F
    COLLARD, JF
    JULIEN, JP
    [J]. CELL, 1993, 73 (01) : 35 - 46
  • [5] Part II:: α-synuclein and its molecular pathophysiological role in neurodegenerative disease
    Dev, KK
    Hofele, K
    Barbieri, S
    Buchman, VL
    van der Putten, H
    [J]. NEUROPHARMACOLOGY, 2003, 45 (01) : 14 - 44
  • [6] Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts
    Duan, WR
    Garner, DS
    Williams, SD
    Funckes-Shippy, CL
    Spath, IS
    Blomme, EAG
    [J]. JOURNAL OF PATHOLOGY, 2003, 199 (02) : 221 - 228
  • [7] A Drosophila model of Parkinson's disease
    Feany, MB
    Bender, WW
    [J]. NATURE, 2000, 404 (6776) : 394 - 398
  • [8] Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein
    Giasson, BI
    Duda, JE
    Quinn, SM
    Zhang, B
    Trojanowski, JQ
    Lee, VMY
    [J]. NEURON, 2002, 34 (04) : 521 - 533
  • [9] Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation
    Gispert, S
    Del Turco, D
    Garrett, L
    Chen, A
    Bernard, DJ
    Hamm-Clement, J
    Korf, HW
    Deller, T
    Braak, H
    Auburger, G
    Nussbaum, RL
    [J]. MOLECULAR AND CELLULAR NEUROSCIENCE, 2003, 24 (02) : 419 - 429
  • [10] Motor dysfunction and gliosis with preserved dopaminergic markers in human α-synuclein A30P transgenic mice
    Gomez-Isla, T
    Irizarry, MC
    Mariash, A
    Cheung, B
    Soto, O
    Schrump, S
    Sondel, J
    Kotilinek, L
    Day, J
    Schwarzschild, MA
    Cha, JHJ
    Newell, K
    Miller, DW
    Uéda, K
    Young, AB
    Hyman, BT
    Ashe, KH
    [J]. NEUROBIOLOGY OF AGING, 2003, 24 (02) : 245 - 258